Global Disease Control and Prevention Vaccine Market Size By Type (Live-Attenuated, Inactivated), By Application (Pediatric Vaccine, Adult Vaccine), By Region, And Segment Forecasts, 2023 to 2032

The Global Disease Control and Prevention Vaccine Market was valued at USD 52.7 billion in 2023 and is expected to reach USD 97.5 billion by 2031, expanding at a CAGR of 8.1% during the forecast period from 2023 to 2031. The market's growth is driven by the increasing incidence of infectious diseases, the rise in global immunization initiatives, and advancements in biotechnology and vaccine development. Heightened awareness of public health, supported by government and non-governmental organization (NGO) vaccination programs, has fueled market demand. Additionally, the continued emphasis on pandemic preparedness and emerging zoonotic threats is reinforcing the need for robust vaccine development and distribution systems.

Drivers

1. Rising Prevalence of Infectious Diseases

Outbreaks of diseases such as influenza, measles, tuberculosis, and emerging threats like COVID-19 have emphasized the critical need for effective vaccine-based prevention strategies globally.

2. Government and NGO Immunization Programs

Global health agencies like the WHO, GAVI, and UNICEF are promoting universal vaccination coverage, especially in low- and middle-income countries, providing vital support to vaccine producers and boosting market growth.

3. Advancements in Vaccine Technology

New technologies including mRNA, vector-based vaccines, and nanoparticle carriers have revolutionized vaccine efficacy, development timelines, and adaptability to future disease threats.

Restraints

1. High Development and Regulatory Costs

Vaccine R&D and clinical trials require significant investment and are subject to rigorous regulatory approvals, posing barriers for smaller players.

2. Vaccine Hesitancy and Misinformation

Public mistrust due to misinformation, particularly around vaccine safety, remains a challenge in achieving global immunization targets.

Opportunity

1. Expansion in Emerging Markets

Growing healthcare infrastructure and increasing disease awareness in countries like India, Brazil, and several African nations offer strong growth potential for vaccine manufacturers.

2. Investment in Pandemic Preparedness and Universal Vaccines

Governments and private sectors are investing in pan-pathogen and universal vaccine platforms, presenting new market opportunities.

Market by System Type Insights

Based on system type, the Live Attenuated Vaccines segment held the largest market share in 2023 due to their long-lasting immunity benefits. However, the mRNA Vaccine segment is projected to grow at the fastest CAGR during the forecast period, driven by successful COVID-19 applications and scalability.

Market by End-use Insights

In 2023, the Public Health Institutions segment dominated the market with more than 55% share. This is attributed to large-scale immunization campaigns conducted by governments and global health organizations. Meanwhile, the Private Clinics and Hospitals segment is expected to grow steadily due to increasing adoption of premium vaccines and adult immunization trends.

Market by Regional Insights

North America accounted for the largest revenue share in 2023, supported by advanced healthcare infrastructure, strong R&D, and proactive vaccination policies. Asia-Pacific is projected to register the fastest growth rate, with countries like India and China expanding immunization coverage and domestic vaccine production.

Competitive Scenario

Key players in the Global Disease Control and Prevention Vaccine Market include:

Pfizer Inc.

GlaxoSmithKline plc

Moderna, Inc.

Sanofi S.A.

Merck & Co., Inc.

Bharat Biotech

Serum Institute of India

Johnson & Johnson

CSL Limited

Sinovac Biotech Ltd.

These companies are focusing on strategic collaborations, regional expansions, and next-generation vaccine innovations. For example:

In 2023, Moderna expanded its global vaccine production network by setting up an mRNA facility in Kenya.

Pfizer announced new mRNA-based vaccine pipelines targeting RSV and influenza in 2024.

In 2025, the Serum Institute of India signed a partnership with GAVI to deliver affordable vaccines to low-income countries.

Scope of Work – Global Disease Control and Prevention Vaccine Market

Key Market Developments

August 2023: Sanofi and GSK received WHO prequalification for their RSV vaccine, making it eligible for global procurement programs.

February 2024: Pfizer launched a maternal vaccine against Group B Streptococcus aimed at newborn disease prevention.

April 2025: Johnson & Johnson entered into a public-private partnership to develop a universal flu vaccine targeting multiple virus strains.

FAQs

1) What is the current market size of the Global Disease Control and Prevention Vaccine Market?

The market was valued at USD 52.7 billion in 2023.

2) What is the major growth driver of the Global Disease Control and Prevention Vaccine Market?

The major growth driver is the rising prevalence of infectious diseases and expanding immunization programs.

3) Which is the largest region during the forecast period in the Global Disease Control and Prevention Vaccine Market?

North America is the largest region due to strong healthcare infrastructure and innovation.

4) Which segment accounted for the largest market share in Global Disease Control and Prevention Vaccine Market?

The Live Attenuated Vaccines segment held the largest share in 2023.

5) Who are the key market players in the Global Disease Control and Prevention Vaccine Market?

Key players include Pfizer, Moderna, GSK, Sanofi, Merck, Serum Institute of India, and Johnson & Johnson.